Discover open access scientific publications

Search, annotate, share and cite publications

Publications by David M. O’Malley

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study

Journal of Clinical Oncology

English

Related publications

A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study 0231D

English

Adjuvant Therapy for Early Uterine High-Grade Leiomyosarcoma

Journal of Clinical Oncology

English

The Role of Racial Genetic Admixture With Endometrial Cancer Outcomes: An NRG Oncology/Gynecologic Oncology Group Study

English

A Phase II Evaluation of Nintedanib (BIBF-1120) in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

English

Gynecologic Oncology Group Study 229C: Personal Reflection

Proceedings in Obstetrics and Gynecology

2013

English

Associations Between Etiologic Factors and Mortality After Endometrial Cancer Diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 Trial

English

A Randomized Trial of Radiotherapy Versus Radiotherapy Plus CCNU for Incompletely Resected Low-Grade Gliomas: A Southwest Oncology Group Study

Journal of Neurosurgery

Surgery

Neurology

1993

English

The Association Between Timing of Initiation of Adjuvant Therapy and the Survival of Early Stage Ovarian Cancer Patients – An Analysis of NRG Oncology/Gynecologic Oncology Group Trials

English

A Phase II Evaluation of Selumetinib (AZD6244, ARRY-142886), a Selective MEK-1/2 Inhibitor in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by David M. O’Malley

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study

Related publications

A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study 0231D

Adjuvant Therapy for Early Uterine High-Grade Leiomyosarcoma

The Role of Racial Genetic Admixture With Endometrial Cancer Outcomes: An NRG Oncology/Gynecologic Oncology Group Study

A Phase II Evaluation of Nintedanib (BIBF-1120) in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

Gynecologic Oncology Group Study 229C: Personal Reflection

Associations Between Etiologic Factors and Mortality After Endometrial Cancer Diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 Trial

A Randomized Trial of Radiotherapy Versus Radiotherapy Plus CCNU for Incompletely Resected Low-Grade Gliomas: A Southwest Oncology Group Study

The Association Between Timing of Initiation of Adjuvant Therapy and the Survival of Early Stage Ovarian Cancer Patients – An Analysis of NRG Oncology/Gynecologic Oncology Group Trials

A Phase II Evaluation of Selumetinib (AZD6244, ARRY-142886), a Selective MEK-1/2 Inhibitor in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study